{
  "docId": "019de070-c9e1-7644-aac7-afa340d8795d",
  "docSlug": "fc9db8b68eed863ebdeb09cbc0c7e18a",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 86 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 86,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 24,
  "notes": "The slide uses stacked bar charts to show revenue composition by region (US, Europe, ERoW, EM) for each product.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c9e1-7644-aac7-afa340d8795d/6",
  "deckHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d",
  "deckJsonHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d.json",
  "deckAnchorHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.22,
        "x": 0.036,
        "y": 0.25
      },
      "kind": "chart",
      "text": "T2D and HF revenue growth 2017-2020",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f61fb0d-ccde-4e63-a1c2-34a87aa11e59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.22,
        "x": 0.27,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Severe asthma revenue growth 2018-2020",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7758f998-f80f-45f2-ba45-a0a416d56c0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.22,
        "x": 0.51,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Hyperkalaemia revenue growth 2019-2020",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8b5d8ee-0beb-44b1-8ab0-f3b5fca859d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.22,
        "x": 0.75,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Anaemia of CKD revenue growth H1-H2 2020",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05b8463e-1663-451e-ba30-d1899d178e08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.23,
        "x": 0.74,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Total revenue booked by AstraZeneca. Collaboration with FibroGen Inc. which booked in-market sales ($72.5m) in China in 2020.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56d21c7c-4b67-487d-b5ab-720cc6b51979",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.48,
        "x": 0.036,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Product Sales at actual exchange rates. 1. Type-2 diabetes 2. Heart failure 3. Chronic kidney disease 4. Leading novel biologic medicine in severe asthma in many markets based on new to brand prescriptions.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd9f06cf-df46-4bcb-a953-a495dc887881",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.93,
        "x": 0.036,
        "y": 0.82
      },
      "kind": "subtitle",
      "text": "CKD under review; A leading biologic medicine; Accelerated momentum; Strong start in China",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ecdff91-5225-4994-86f2-2d4f3c4f6187",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.46,
        "x": 0.036,
        "y": 0.045
      },
      "kind": "title",
      "text": "Strong commercial execution",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e3a6f50-8835-4052-b9b7-e800b19db415",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "d00c0ca8-3f4a-4d38-ba80-a06664369961",
      "evidence": "chart/bar-vertical: Anaemia of CKD revenue growth H1-H2 2020, chart/bar-stacked: Severe asthma revenue growth 2018-2020",
      "confidence": 0.7
    },
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "95a19ed6-7af9-44a9-aeea-e8560d3ca81a",
      "evidence": "subtitle: CKD under review; A leading biologic medicine; Accelerated momentum; Strong start in China",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 6,
      "beatId": "53f0349c-2875-43c1-afc2-508c894a24fb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 6-11 outline AstraZeneca's strategy and pipeline",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b33573ac-7b22-4c15-b7fd-41ed02874b9c",
      "evidence": "Slides 4-9 emphasize the need for improved treatment options",
      "position": 0,
      "objective": "Highlight the cost of inaction in transforming treatment for chronic diseases",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}